All articles by William Newton

William Newton

@WillNewton19

William Newton is a Senior Reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing on clinical trial design, healthcare business and regulation, and new technologies. Now based in New York City, he previously covered diabetes drug development at Close Concerns’ industry-facing publication in San Francisco. William holds a BA in Economics from Williams College.

Pharma, patient advocates clash over Inflation Reduction Act

The Inflation Reduction Act, which became US law in August 2022, has invited its fair share of critics and supporters…
WHO declares end of Covid-19 public health emergency

The World Health Organization (WHO) announced the end of the public health emergency for Covid-19, marking the end of a…
Successive AdCom wins for bluebird bio cue encouraging signs for rare disease gene therapies

In back-to-back US Food and Drug Administration (FDA) Advisory Committee (AdCom) meetings last week, panelists voted unanimously in favour of…
Can Relmada’s fast-acting pill for major depressive disorder compete in a crowded market?

For decades, most patients with depression have had access to cheap, generic selective serotonin reuptake inhibitors, or SSRIs. Now, a…
An oral pill for alcohol abuse vies to enter a quickly evolving market

An estimated 100 million people suffer from alcohol abuse disorder (AUD) worldwide with health authorities citing the condition as a…

An uphill battle for insulin pricing reform as copay cap bill enters US Senate

Skyrocketing insulin prices in the US have acted as a poster child for a healthcare system plagued by escalating costs…
Insulin pricing: could an e-commerce approach cut costs?

As insulin prices continue to soar, the advent of e-commerce drug manufacturers could provide a path to cheaper insulin. But…
Amylyx AdCom: panelists narrowly vote against FDA approval

In yesterday’s FDA Advisory Committee (AdCom) meeting, panelists voted six to four against approving Amylyx’s AMX0035 for amyotrophic lateral sclerosis…
Navigating distribution challenges for rare disease drugs

Bringing a new treatment for a rare disorder to market is often only half the challenge. Reaching niche patient populations,…
Narrow FDA panel vote on Merck’s molnupiravir bolsters outlook on mAbs

Need to Know: Lower efficacy with updated data causes favor to shift toward mAbs Safety questions come to the forefront…